Navigation Links
COUP-TFII sparks prostate cancer progression
Date:11/28/2012

HOUSTON (Nov. 29, 2012) Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive treatment?

Drs. Ming-Jer and Sophia Tsai, both professors in the department of molecular and cellular biology at Baylor College of Medicine, think a receptor called COUP-TFII that they have long studied may point the way to an answer. In a study that appears online in the journal Nature, they show that high levels (overexpression) of COUP-TFII can overcome a natural barrier to progression of prostate cancer, allowing tumor cells to grow and spread throughout the body a process called metastasis.

"Levels of COUP-TFII provide a good prognostic marker for prostate cancer when added to other known markers of the disease," said Dr. Ming-Jer Tsai.

"COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis," said Dr. Sophia Tsai. In other words, one "hit" or mutation might start the process of cells becoming cancerous. The second "hit" would make them more aggressive.

In studies of patient samples, loss of a protein called PTEN or mutations in another signaling pathway called PI3K show up in prostate tumors. However, tumors in which PTEN is lost can remain indolent. One theory is that loss of PTEN increases TGF-beta signaling, which creates a barrier to prostate cancer progression.

The Tsais' studies in mice that lack PTEN show that loss of COUP-TFII inhibits the development of prostate tumors in the animals. When mice have a gene that produces insufficient levels of PTEN, COUP-TFII overexpression enhances prostate tumor progression. Further studies in mice that lost PTEN showed that high levels of COUP-TFII promoted the metastatic spread of the prostate cancer.

Studies in cell cultures and in human tissues confirmed the activity of COUP-TFII in promoting a more aggressive form of prostate cancer that could spread and metastasize.

The next step is find out how to inhibit COUP-TFII and prevent so-called indolent prostate cancers from becoming more aggressive, said Ming-Jer Tsai.


'/>"/>

Contact: Dipali Pathak
pathak@bcm.edu
713-713-4710
Baylor College of Medicine
Source:Eurekalert

Related medicine news :

1. Early treatment sparks striking brain changes in autism
2. UAlberta prostate cancer researcher and team developing homing beacon drugs to target cancer cells
3. Prostate Cancer Websites Often Hard to Understand: Study
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
6. Active surveillance can reduce suffering among men with prostate cancer
7. Prostate cancer prognosis hope
8. Proton therapy treatment preserves quality of life for men with prostate cancer
9. For many prostate cancer patients, Web sites are too difficult to read
10. Viagra Can Help Prostate Cancer Patients Maintain Sex Lives: Study
11. Drop in testosterone tied to prostate cancer recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... organization behind the New England Journal of Medicine and NEJM Journal Watch, announces ... Pediatrics Board Review was created by a panel of pediatricians from leading medical ...
(Date:3/27/2017)... Birmingham, Clarkston, and Lake Orion, Michigan (PRWEB) , ... ... ... can affect weight loss results. The comprehensive weight management program at Women’s ... begins with an initial evaluation and physical exam. The specialists at ...
(Date:3/27/2017)... Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in ... of the best days I’ve had in a long time,” she said. , She thinks ... lot of money that I never thought I would have to help my students.” , ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
(Date:3/26/2017)... (PRWEB) , ... March 26, 2017 , ... ... worldwide to receive the RealSelf 100 Award, a prestigious award honoring the top ... procedures and to find and connect with doctors and clinics. , In 2016, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Columbia, March 27, 2017  Sophiris Bio Inc. ... "Sophiris"), a clinical late-stage biopharmaceutical company developing topsalysin ... diseases, today reported fourth quarter and full year ... Key Corporate Highlights: ... Prostate Cancer. During 2016, the Company reported successful ...
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... 2017  iCAD (Nasdaq: ICAD), an industry-leading provider ... therapy for the early identification and treatment of ... Premarket Approval (PMA) from the U.S. Food and ... first-of-its-kind, concurrent-read computer aided detection solution for digital ... available on the PowerLook® Breast Health Solutions platform.  ...
Breaking Medicine Technology: